NTRK Fusion Gene Positive Advanced Solid Tumor Market Analysis Covering Size, Share

“Global NTRK Fusion Gene Positive Advanced Solid Tumor market is anticipated to grow with a CAGR of nearly 5.4%, during the forecast period 2022-2031. NTRK fusion gene positive cancers are those in which the NTRK gene has been mutated. While NTRK fusions are uncommon, accounting for less than 1% of solid tumors, the exact prevalence is unknown. NTRK fusion genes can be detected using DNA Next Generation Sequencing (NSG) technology. It has a high level of sensitivity and accuracy. It is capable of detecting gene partners with significant therapeutic effects. Foundation One does not detect NTRK fusions using commercially available techniques such as DNA NGS panels. Due to technological advances, the global NTRK fusion gene positive advanced solid tumors market is expected to expand rapidly over the forecast period. The demand for NTRK fusion gene positive advanced solid tumors would benefit from early screening and identification of NTRK mutation genes in people. Due to the advancement of new therapeutics in the near future for treating various forms of cancers, the global NTRK fusion gene positive advanced solid tumours market has a high potential. NTRK inhibitors, such as Entrectinib, marketed by Genentech Inc., were recently licensed by the FDA in 2019, for the treatment of NTRK fusion gene positive advanced solid tumors. Likewise,, SeraCare Life Sciences, a foremost in vitro diagnostics producer and clinical laboratory partner, launched an extended neurotrophic tropomyosin receptor kinase (NTRK) RNA fusion reference material panel in 2018, established in collaboration with Bayer. However, Poor healthcare infrastructure and high costs associated with genetic screening of NTRK fusion genes may hamper growth of NTRK fusion gene positive advanced solid tumors market growth over the forecast period of 2020-2027.

Download Sample PDF of this Report: –  https://www.sdki.jp/sample-request-112111

The regional analysis of the global NTRK Fusion Gene Positive Advanced Solid Tumors Market is considered for the key regions such as Asia Pacific, North America, Europe, Latin America, and Rest of the World. North America is the leading/significant region across the world in terms of market share due to rising cancer clinical research and development activities in the region. Whereas Europe is also anticipated to exhibit the highest growth rate / CAGR over the forecast period 2020-2027, due to early diagnosis and treatment adoption across the region.

Major market player included in this report are:

Bayer AG
Teva Pharmaceuticals
Empire Genomics, LLC.
SeraCare Life Sciences
F. Hoffmann-La Roche Ltd
NeoGenomics Laboratories, Inc.
Glaxosmithkline plc
Merck & Co.
Daiichi Sankyo Company Limited
S Deciphera Pharmaceuticals, Inc.

NTRK Fusion Gene Positive Advanced Solid Tumor Market
Enzymes Market
Ophthalmic Operating Room Microscope Market
Sleep Apnea Diagnostics Market
Point of Care Diagnostic and Testing Market
Medical Payment Fraud Detection Market
Brain Implants Market
Brachytherapy Market
Blood Pressure Monitoring Devices Market
Aromatherapy Market

Related posts

Leave a Comment